Diabetic nephropathy and antioxidants
GLP-1RAs for NASH GLP-1RAs have significantly improved the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD
For individuals with metabolic risk factors, insulin resistance, chronic inflammation, or a family history of obesity-associated cancers, GLP-1 therapy in the context of a comprehensive, physician-guided longevity programme may represent a valuable adjunct to conventional preventive medicine strategies
COPD as a Disease of Accelerated Lung Aging
differences in how the drugs work: Ozempic is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist